Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes
Using a real-world dataset, semaglutide, tirzepatide and BS, interventions shown to elicit weight loss and improve glycaemic control, have a myriad of benefits on cardio-renal outcomes and mortality, supporting their use as disease-modifying therapy options in T2DM and CKD.
Authors
- Joseph J. Henson (ORCID: https://orcid.org/0000-0002-3898-7053)
- Dimitris Papamargaritis (ORCID: https://orcid.org/0000-0001-5044-1515)
- Thomas J. Wilkinson (ORCID: https://orcid.org/0000-0002-7855-7752)
- David Webb
- Thomas E. Yates (ORCID: https://orcid.org/0000-0002-5724-5178)
- Jonathan Goldney (ORCID: https://orcid.org/0000-0001-8553-8296)
- Francesco Zaccardi (ORCID: https://orcid.org/0000-0002-2636-6487)
- Kamlesh K. Khunti (ORCID: https://orcid.org/0000-0003-2343-7099)
- Melanie Jane Davies (ORCID: https://orcid.org/0000-0002-9987-9371)
Institutions
- Leicester General Hospital (GB)
- University Hospitals of Leicester NHS Trust (GB)
- NIHR Leicester Biomedical Research Centre (GB)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1093/ndt/gfaf258
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- NIHR Leicester Biomedical Research Centre